Evaluation and Medico-Economic Study of FIBROSCAN in Patients With Viral Hepatitis
Sponsored by Assistance Publique - Hôpitaux de Paris
About this trial
Last updated 16 years ago
Study ID
IC0504
Status
Terminated
Type
Observational
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 17 years ago
What is this trial about?
A new approach to the evaluation of liver fibrosis has been proposed using PULSOMETRY.
The objective is to evaluate the diagnostic performances of the FIBROSCAN technique,
together with non-invasive techniques, and to determine how it is able to predict the
histological fibrosis score, defined by the METAVIR score. This transversal study aims to
compare the evaluation of hepatic fibrosis obtained by FIBROSCAN and histology (METAVIR
score) in 2550 consecutive patients taken in charge for a liver biopsy. The results of
the study will compare the respective performances of these techniques in the prediction
of the METAVIR score, and help in the recommendation of the care of patients with viral
hepatitis B and C; these methods will undergo a medico-economic study.
What are the participation requirements?
Inclusion Criteria
- Chronic hepatitis B or C
- With liver biopsy indication
- Patient information
Exclusion Criteria
- Drug hepatitis
- Metabolic hepatology
- Steatosis or non-alcoholic steatohepatitis
- Autoimmune hepatopathy
- Non-contraindication to liver biopsy
- Non-contraindication to FIBROSCAN examination
- Ascites
- Obesity